Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.
NCT04736433 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6066
Last updated 2023-08-01
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
ACE inhibitor
ACE inhibitor dispensing claim is used as the reference
- DRUG
-
Sacubitril/Valsartan
Sacubitril/Valsartan dispensing claim is used as the reference
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-22
- Primary Completion
- 2021-02-18
- Completion
- 2021-02-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
NCT03292653 ·Status: TERMINATED ·Phase: PHASE2
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
NCT04986202 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
NCT06639087 ·Status: TERMINATED ·Phase: PHASE1
-
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty
NCT04743063 ·Status: UNKNOWN
-
Impact of Vericiguat on Hemodynamics of Heart Failure
NCT05704478 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
NCT03756285 ·Status: TERMINATED ·Phase: PHASE2
-
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
NCT05096143 ·Status: COMPLETED
-
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
NCT06142383 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
NCT05139615 ·Status: TERMINATED ·Phase: PHASE2
-
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
NCT04157751 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652 ·Status: RECRUITING ·Phase: PHASE3
-
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models
NCT05096039 ·Status: COMPLETED
-
Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction
NCT05487261 ·Status: RECRUITING ·Phase: PHASE4
-
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
NCT03300427 ·Status: COMPLETED ·Phase: PHASE4
-
Tezosentan in Acute Heart Failure
NCT00525707 ·Status: COMPLETED ·Phase: PHASE3
-
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
NCT04735354 ·Status: COMPLETED
-
Ertugliflozin in Chronic Heart Failure
NCT04438213 ·Status: RECRUITING ·Phase: PHASE2
-
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
NCT02653482 ·Status: COMPLETED ·Phase: PHASE4
-
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
NCT03447990 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction
NCT04397302 ·Status: COMPLETED
-
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients
NCT05963282 ·Status: COMPLETED